Gaithersburg, MD, October 19, 2015  – MaxCyte® Inc., a world leader in the discovery, development, and manufacture of innovative cell therapies, today announces that it will present its approach to addressing the problem of ‘on-target off-tumor’ toxicity against normal tissue of viral vector-modified CAR T-/NKcells to the Biochemical Society in London on 20th October 2015.


The presentation, to be made at the Biochemical Society’s focused meeting on Chimeric Antigen Receptor Therapy in Haematology and Oncology: Current Successes and Challenges, will be given by Madhusudan V. Peshwa, Executive Vice President of Cellular Therapies at MaxCyte.


Dr. Peshwa will detail how MaxCyte deploys a non-viral approach using mRNA CAR transfection to permit prospective control of ‘on-target off-tumor toxicity’ in multiple solid cancers. Collaborating with multiple academic groups, MaxCyte has enabled translation of mRNA CAR therapy into seven human clinical trials to preliminarily confirm safety and anti-tumor activity.


Doug Doerfler, President & CEO of MaxCyte, Inc. said: “We are excited by the potential of our technology and believe that the use of mRNA has multiple advantages over viral vector technology in the delivery of CAR Therapies. In particular, we believe that our approach has the potential to reduce toxicity to normal tissue as well as target solid tumors, a significant unmet medical need. We look forward to discussing our findings with our colleagues at the Biochemical Society and the wider scientific community.”


About MaxCyte            

Company Overview

Founded in 1999, MaxCyte is focused on the discovery, development, and manufacture of innovative drugs, including cell therapies utilizing best-in-class cell modification technologies.

MaxCyte has developed a next-generation FDA-cleared and CE-marked commercial platform enabling the scalable, fast and reliable engineering of a wide range of cells, including hard-to-transfection human primary cells. MaxCyte facilitates the development of safer, more effective, and lower cost cell-based therapies for a broad range of applications.

The company currently has clinical and pre-clinical-partnered and proprietary products under development. This clinical-grade cell-modification technology is well validated and has received Master File designation with the U.S. FDA. This designation has been instrumental in more than a dozen clinical trials currently in process. The Company’s proprietary mRNA CAR T-cell based platform for immuno-oncology indications including solid cancers is currently being utilised in seven clinical trials.


For more information visit /